{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T14:09:38Z","timestamp":1778940578033,"version":"3.51.4"},"reference-count":58,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,6,7]],"date-time":"2024-06-07T00:00:00Z","timestamp":1717718400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008069","name":"UCSF","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008069","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009730","name":"Stand Up To Cancer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009730","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P30 CA082103"],"award-info":[{"award-number":["P30 CA082103"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["K99\/R00 CA181494"],"award-info":[{"award-number":["K99\/R00 CA181494"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Neoplasia"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.bneo.2024.100025","type":"journal-article","created":{"date-parts":[[2024,6,11]],"date-time":"2024-06-11T00:40:56Z","timestamp":1718066456000},"page":"100025","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Functional multiomics reveals genetic and pharmacologic regulation of surface CD38 in multiple myeloma"],"prefix":"10.1016","volume":"1","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4438-1576","authenticated-orcid":false,"given":"Priya","family":"Choudhry","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3667-8097","authenticated-orcid":false,"given":"Corynn","family":"Kasap","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2622-4822","authenticated-orcid":false,"given":"Bonell","family":"Pati\u00f1o-Escobar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olivia","family":"Gugliemini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5339-5446","authenticated-orcid":false,"given":"Huimin","family":"Geng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vishesh","family":"Sarin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0445-5654","authenticated-orcid":false,"given":"Amrik","family":"Kang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1984-222X","authenticated-orcid":false,"given":"Audrey","family":"Kishishita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7473-4144","authenticated-orcid":false,"given":"Sham","family":"Rampersaud","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7691-0690","authenticated-orcid":false,"given":"Letitia","family":"Sarah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7157-4330","authenticated-orcid":false,"given":"Yu-Hsiu T.","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neha","family":"Paranjape","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Poornima","family":"Ramkumar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1198-6341","authenticated-orcid":false,"given":"Jonathan C.","family":"Patton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Makeba","family":"Marcoulis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Donghui","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Phojanakong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2499-6618","authenticated-orcid":false,"given":"Veronica","family":"Steri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Byron","family":"Hann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9810-3566","authenticated-orcid":false,"given":"Benjamin G.","family":"Barwick","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3819-7019","authenticated-orcid":false,"given":"Martin","family":"Kampmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7465-6964","authenticated-orcid":false,"given":"Arun P.","family":"Wiita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.bneo.2024.100025_bib1","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1007\/s40265-019-01080-6","article-title":"Daratumumab: a review in combination therapy for transplant-ineligible newly diagnosed multiple myeloma","volume":"79","author":"Syed","year":"2019","journal-title":"Drugs"},{"issue":"12","key":"10.1016\/j.bneo.2024.100025_bib2","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1080\/14712598.2018.1544240","article-title":"CD38 as an immunotherapeutic target in multiple myeloma","volume":"18","author":"Bonello","year":"2018","journal-title":"Expert opinion on biological therapy"},{"key":"10.1016\/j.bneo.2024.100025_bib3","doi-asserted-by":"crossref","first-page":"2134","DOI":"10.3389\/fimmu.2018.02134","article-title":"CD38 antibodies in multiple myeloma: mechanisms of action and modes of resistance","volume":"9","author":"van de Donk","year":"2018","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.bneo.2024.100025_bib4","doi-asserted-by":"crossref","DOI":"10.3390\/cells9010167","article-title":"Mechanisms of Resistance to Anti-CD38 Daratumumab in Multiple Myeloma","volume":"9","author":"Saltarella","year":"2020","journal-title":"Cells"},{"issue":"7","key":"10.1016\/j.bneo.2024.100025_bib5","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1182\/blood-2016-03-703439","article-title":"CD38 expression and complement inhibitors affect response and resistance to daratumumab therapy in myeloma","volume":"128","author":"Nijhof","year":"2016","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.bneo.2024.100025_bib6","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1080\/19420862.2015.1007813","article-title":"Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myeloma","volume":"7","author":"Overdijk","year":"2015","journal-title":"MAbs"},{"issue":"3","key":"10.1016\/j.bneo.2024.100025_bib7","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1182\/blood-2015-12-687749","article-title":"Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma","volume":"128","author":"Krejcik","year":"2016","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.bneo.2024.100025_bib8","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1038\/s41375-020-0810-4","article-title":"Daratumumab induces mechanisms of immune activation through CD38+ NK cell targeting","volume":"35","author":"Viola","year":"2021","journal-title":"Leukemia"},{"issue":"24","key":"10.1016\/j.bneo.2024.100025_bib9","doi-asserted-by":"crossref","first-page":"7498","DOI":"10.1158\/1078-0432.CCR-17-2027","article-title":"Monocytes and Granulocytes Reduce CD38 Expression Levels on Myeloma Cells in Patients Treated with Daratumumab","volume":"23","author":"Krejcik","year":"2017","journal-title":"Clinical cancer research : an official journal of the American Association for Cancer Research"},{"issue":"2","key":"10.1016\/j.bneo.2024.100025_bib10","doi-asserted-by":"crossref","first-page":"378","DOI":"10.3390\/cells9020378","article-title":"Controversy in the Use of CD38 Antibody for Treatment of Myeloma: Is High CD38 Expression Good or Bad?","volume":"9","author":"Plesner","year":"2020","journal-title":"Cells"},{"issue":"1","key":"10.1016\/j.bneo.2024.100025_bib11","doi-asserted-by":"crossref","first-page":"e37","DOI":"10.3324\/haematol.2019.219683","article-title":"Pre-treatment CD38-positive regulatory T cells affect the durable response to daratumumab in relapsed\/refractory multiple myeloma patients","volume":"105","author":"Kitadate","year":"2020","journal-title":"Haematologica"},{"issue":"10","key":"10.1016\/j.bneo.2024.100025_bib12","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1038\/leu.2015.123","article-title":"Upregulation of CD38 expression on multiple myeloma cells by all-trans retinoic acid improves the efficacy of daratumumab","volume":"29","author":"Nijhof","year":"2015","journal-title":"Leukemia"},{"issue":"25","key":"10.1016\/j.bneo.2024.100025_bib13","doi-asserted-by":"crossref","first-page":"3386","DOI":"10.1182\/blood-2017-03-770776","article-title":"Panobinostat induces CD38 upregulation and augments the antimyeloma efficacy of daratumumab","volume":"129","author":"Garcia-Guerrero","year":"2017","journal-title":"Blood"},{"issue":"20","key":"10.1016\/j.bneo.2024.100025_bib14","doi-asserted-by":"crossref","first-page":"2166","DOI":"10.1182\/blood-2018-05-850727","article-title":"IMiDs prime myeloma cells for daratumumab-mediated cytotoxicity through loss of Ikaros and Aiolos","volume":"132","author":"Fedele","year":"2018","journal-title":"Blood"},{"issue":"20","key":"10.1016\/j.bneo.2024.100025_bib15","doi-asserted-by":"crossref","first-page":"2334","DOI":"10.1182\/blood.2019004332","article-title":"The JAK-STAT pathway regulates CD38 on myeloma cells in the bone marrow microenvironment: therapeutic implications","volume":"136","author":"Ogiya","year":"2020","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.bneo.2024.100025_bib16","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1038\/s41375-019-0587-5","article-title":"DNA methyltransferase inhibitors upregulate CD38 protein expression and enhance daratumumab efficacy in multiple myeloma","volume":"34","author":"Choudhry","year":"2020","journal-title":"Leukemia"},{"issue":"23","key":"10.1016\/j.bneo.2024.100025_bib17","doi-asserted-by":"crossref","first-page":"5128","DOI":"10.1182\/bloodadvances.2021005220","article-title":"Efficacy and Safety of Daratumumab Combined With All-Trans Retinoic Acid in Relapsed\/Refractory Multiple Myeloma","volume":"5","author":"Frerichs","year":"2021","journal-title":"Blood Adv"},{"issue":"1","key":"10.1016\/j.bneo.2024.100025_bib18","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1038\/s43018-019-0004-z","article-title":"Trispecific antibodies enhance the therapeutic efficacy of tumor-directed T cells through T cell receptor co-stimulation","volume":"1","author":"Wu","year":"2020","journal-title":"Nat Cancer"},{"issue":"6","key":"10.1016\/j.bneo.2024.100025_bib19","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1080\/10428194.2022.2030476","article-title":"A combination of humanized anti-BCMA and murine anti-CD38 CAR-T cell therapy in patients with relapsed or refractory multiple myeloma","volume":"63","author":"Zhang","year":"2022","journal-title":"Leuk Lymphoma"},{"issue":"8","key":"10.1016\/j.bneo.2024.100025_bib20","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/j.trecan.2018.05.005","article-title":"Seeking convergence and cure with new myeloma therapies","volume":"4","author":"Choudhry","year":"2018","journal-title":"Trends Cancer"},{"issue":"13","key":"10.1016\/j.bneo.2024.100025_bib21","doi-asserted-by":"crossref","first-page":"2899","DOI":"10.1182\/bloodadvances.2019001346","article-title":"CRISPR-based screens uncover determinants of immunotherapy response in multiple myeloma","volume":"4","author":"Ramkumar","year":"2020","journal-title":"Blood Adv"},{"issue":"8","key":"10.1016\/j.bneo.2024.100025_bib22","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1038\/nprot.2014.103","article-title":"Functional genomics platform for pooled screening and generation of mammalian genetic interaction maps","volume":"9","author":"Kampmann","year":"2014","journal-title":"Nat Protoc"},{"issue":"2","key":"10.1016\/j.bneo.2024.100025_bib23","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.neuron.2019.07.014","article-title":"CRISPR Interference-Based Platform for Multimodal Genetic Screens in Human iPSC-Derived Neurons","volume":"104","author":"Tian","year":"2019","journal-title":"Neuron"},{"issue":"19","key":"10.1016\/j.bneo.2024.100025_bib24","doi-asserted-by":"crossref","first-page":"2138","DOI":"10.1182\/blood-2017-09-808063","article-title":"Active enhancer and chromatin accessibility landscapes chart the regulatory network of primary multiple myeloma","volume":"131","author":"Jin","year":"2018","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.bneo.2024.100025_bib25","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1093\/bioinformatics\/18.2.333","article-title":"PROMO: detection of known transcription regulatory elements using species-tailored searches","volume":"18","author":"Messeguer","year":"2002","journal-title":"Bioinformatics"},{"issue":"4","key":"10.1016\/j.bneo.2024.100025_bib26","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1038\/nbt.1532","article-title":"Mass-spectrometric identification and relative quantification of N-linked cell surface glycoproteins","volume":"27","author":"Wollscheid","year":"2009","journal-title":"Nat Biotechnol"},{"issue":"8","key":"10.1016\/j.bneo.2024.100025_bib27","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1158\/2159-8290.CD-20-0242","article-title":"Surface proteomics reveals CD72 as a target for in vitro-evolved nanobody-based CAR-T cells in KMT2A\/MLL1-rearranged B-ALL","volume":"11","author":"Nix","year":"2021","journal-title":"Cancer Discov"},{"issue":"21","key":"10.1016\/j.bneo.2024.100025_bib28","doi-asserted-by":"crossref","first-page":"3214","DOI":"10.1182\/bloodadvances.2019000303","article-title":"Integrated phosphoproteomics and transcriptional classifiers reveal hidden RAS signaling dynamics in multiple myeloma","volume":"3","author":"Lin","year":"2019","journal-title":"Blood Adv"},{"issue":"12","key":"10.1016\/j.bneo.2024.100025_bib29","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.1038\/nprot.2016.136","article-title":"The MaxQuant computational platform for mass spectrometry-based shotgun proteomics","volume":"11","author":"Tyanova","year":"2016","journal-title":"Nat Protoc"},{"issue":"3","key":"10.1016\/j.bneo.2024.100025_bib30","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1016\/j.cell.2014.09.029","article-title":"Genome-Scale CRISPR-Mediated Control of Gene Repression and Activation","volume":"159","author":"Gilbert","year":"2014","journal-title":"Cell"},{"issue":"12","key":"10.1016\/j.bneo.2024.100025_bib58","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1186\/s13059-014-0554-4","article-title":"MAGeCK enables robust identification of essential genes from genome-scale CRISPR\/Cas9 knockout screens","volume":"15","author":"Li","year":"2014","journal-title":"Genome Biol"},{"issue":"9","key":"10.1016\/j.bneo.2024.100025_bib31","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1177\/1087057112455060","article-title":"Screening for inhibitors of an essential chromatin remodeler in mouse embryonic stem cells by monitoring transcriptional regulation","volume":"17","author":"Dykhuizen","year":"2012","journal-title":"J Biomol Screen"},{"key":"10.1016\/j.bneo.2024.100025_bib32","article-title":"The oncometabolite 2-hydroxyglutarate activates the mTOR signalling pathway","volume":"712700","author":"Carbonneau","year":"2016","journal-title":"Nat Commun"},{"issue":"4","key":"10.1016\/j.bneo.2024.100025_bib33","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1080\/21541264.2018.1429836","article-title":"Hexim1, an RNA-controlled protein hub","volume":"9","author":"Michels","year":"2018","journal-title":"Transcription"},{"issue":"5","key":"10.1016\/j.bneo.2024.100025_bib34","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/j.gde.2008.07.010","article-title":"Context-dependent regulation of Groucho\/TLE-mediated repression","volume":"18","author":"Cinnamon","year":"2008","journal-title":"Curr Opin Genet Dev"},{"key":"10.1016\/j.bneo.2024.100025_bib35","doi-asserted-by":"crossref","first-page":"300","DOI":"10.3389\/fgene.2015.00300","article-title":"A\u00a0new age in functional genomics using CRISPR\/Cas9 in arrayed library screening","volume":"6","author":"Agrotis","year":"2015","journal-title":"Front Genet"},{"issue":"8","key":"10.1016\/j.bneo.2024.100025_bib36","first-page":"2989","article-title":"DNA methyltransferase inhibitors and their emerging role in epigenetic therapy of cancer","volume":"33","author":"Gnyszka","year":"2013","journal-title":"Anticancer Res"},{"key":"10.1016\/j.bneo.2024.100025_bib37","article-title":"NF-kappaB dysregulation in multiple myeloma","volume":"3968-76","author":"Matthews","year":"2016","journal-title":"Semin Cancer Biol"},{"issue":"6844","key":"10.1016\/j.bneo.2024.100025_bib38","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1038\/35085509","article-title":"Plasma cell differentiation requires the transcription factor XBP-1","volume":"412","author":"Reimold","year":"2001","journal-title":"Nature"},{"issue":"8","key":"10.1016\/j.bneo.2024.100025_bib39","doi-asserted-by":"crossref","first-page":"3177","DOI":"10.1182\/blood-2006-09-044974","article-title":"Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomib","volume":"109","author":"Mulligan","year":"2007","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.bneo.2024.100025_bib40","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1038\/nbt.1665","article-title":"The MicroArray Quality Control (MAQC)-II study of common practices for the development and validation of microarray-based predictive models","volume":"28","author":"Shi","year":"2010","journal-title":"Nat Biotechnol"},{"issue":"3","key":"10.1016\/j.bneo.2024.100025_bib41","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.ccr.2013.08.009","article-title":"Xbp1s-negative tumor B cells and pre-plasmablasts mediate therapeutic proteasome inhibitor resistance in multiple myeloma","volume":"24","author":"Leung-Hagesteijn","year":"2013","journal-title":"Cancer Cell"},{"issue":"12","key":"10.1016\/j.bneo.2024.100025_bib42","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1038\/s43018-023-00657-1","article-title":"Genomic and immune signatures predict clinical outcome in newly diagnosed multiple myeloma treated with immunotherapy regimens","volume":"4","author":"Maura","year":"2023","journal-title":"Nat Cancer"},{"issue":"34","key":"10.1016\/j.bneo.2024.100025_bib43","doi-asserted-by":"crossref","first-page":"2853","DOI":"10.2217\/fon-2020-0401","article-title":"CD38 as an immunomodulator in cancer","volume":"16","author":"Li","year":"2020","journal-title":"Future Oncol"},{"issue":"6","key":"10.1016\/j.bneo.2024.100025_bib44","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/j.stem.2007.10.001","article-title":"Identification of a hierarchy of multipotent hematopoietic progenitors in human cord blood","volume":"1","author":"Majeti","year":"2007","journal-title":"Cell Stem Cell"},{"issue":"5","key":"10.1016\/j.bneo.2024.100025_bib45","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1016\/j.cell.2015.07.011","article-title":"Inhibiting DNA Methylation Causes an Interferon Response in Cancer via dsRNA Including Endogenous Retroviruses","volume":"162","author":"Chiappinelli","year":"2015","journal-title":"Cell"},{"issue":"5","key":"10.1016\/j.bneo.2024.100025_bib46","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1016\/j.cell.2015.07.056","article-title":"DNA-Demethylating Agents Target Colorectal Cancer Cells by Inducing Viral Mimicry by Endogenous Transcripts","volume":"162","author":"Roulois","year":"2015","journal-title":"Cell"},{"issue":"9","key":"10.1016\/j.bneo.2024.100025_bib47","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1089\/107999099313299","article-title":"Upregulation of CD38 gene expression in leukemic B cells by interferon types I and II","volume":"19","author":"Bauvois","year":"1999","journal-title":"J Interferon Cytokine Res"},{"issue":"5","key":"10.1016\/j.bneo.2024.100025_bib48","doi-asserted-by":"crossref","first-page":"e421","DOI":"10.1038\/bcj.2016.30","article-title":"All-trans retinoic acid and interferon-alpha increase CD38 expression on adult T-cell leukemia cells and sensitize them to T cells bearing anti-CD38 chimeric antigen receptors","volume":"6","author":"Mihara","year":"2016","journal-title":"Blood Cancer J"},{"issue":"10","key":"10.1016\/j.bneo.2024.100025_bib49","doi-asserted-by":"crossref","first-page":"3176","DOI":"10.1158\/1078-0432.CCR-18-1597","article-title":"The mechanism of action of the anti-CD38 monoclonal antibody isatuximab in multiple myeloma","volume":"25","author":"Moreno","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"3","key":"10.1016\/j.bneo.2024.100025_bib50","doi-asserted-by":"crossref","first-page":"807","DOI":"10.4049\/jimmunol.1501351","article-title":"The Therapeutic CD38 Monoclonal Antibody Daratumumab Induces Programmed Cell Death via Fcgamma Receptor-Mediated Cross-Linking","volume":"197","author":"Overdijk","year":"2016","journal-title":"J Immunol"},{"issue":"9","key":"10.1016\/j.bneo.2024.100025_bib51","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1038\/nbt.3327","article-title":"High-throughput phosphoproteomics reveals in vivo insulin signaling dynamics","volume":"33","author":"Humphrey","year":"2015","journal-title":"Nat Biotechnol"},{"issue":"268","key":"10.1016\/j.bneo.2024.100025_bib52","doi-asserted-by":"crossref","first-page":"rs6","DOI":"10.1126\/scisignal.2003573","article-title":"Kinase-substrate enrichment analysis provides insights into the heterogeneity of signaling pathway activation in leukemia cells","volume":"6","author":"Casado","year":"2013","journal-title":"Sci Signal"},{"issue":"1","key":"10.1016\/j.bneo.2024.100025_bib53","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1038\/s41467-024-45561-z","article-title":"Epigenetic regulation of CD38\/CD48 by KDM6A mediates NK cell response in multiple myeloma","volume":"15","author":"Liu","year":"2024","journal-title":"Nat Commun"},{"key":"10.1016\/j.bneo.2024.100025_bib54","article-title":"KDM6A Regulates Immune Response Genes in Multiple Myeloma","author":"Dupere-Richer","year":"2024","journal-title":"bioRxiv"},{"issue":"24","key":"10.1016\/j.bneo.2024.100025_bib55","doi-asserted-by":"crossref","first-page":"5772","DOI":"10.1182\/blood-2011-07-366633","article-title":"Blockade of XBP1 splicing by inhibition of IRE1alpha is a promising therapeutic option in multiple myeloma","volume":"119","author":"Mimura","year":"2012","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.bneo.2024.100025_bib56","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.ccr.2007.07.003","article-title":"Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma","volume":"12","author":"Keats","year":"2007","journal-title":"Cancer Cell"},{"issue":"15","key":"10.1016\/j.bneo.2024.100025_bib57","doi-asserted-by":"crossref","first-page":"3021","DOI":"10.1182\/bloodadvances.2020002440","article-title":"FcepsilonRIgamma-negative NK cells persist in vivo and enhance efficacy of therapeutic monoclonal antibodies in multiple myeloma","volume":"5","author":"Bigley","year":"2021","journal-title":"Blood Adv"}],"container-title":["Blood Neoplasia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950328024000256?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950328024000256?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T13:37:08Z","timestamp":1778938628000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2950328024000256"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":58,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["S2950328024000256"],"URL":"https:\/\/doi.org\/10.1016\/j.bneo.2024.100025","relation":{},"ISSN":["2950-3280"],"issn-type":[{"value":"2950-3280","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Functional multiomics reveals genetic and pharmacologic regulation of surface CD38 in multiple myeloma","name":"articletitle","label":"Article Title"},{"value":"Blood Neoplasia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bneo.2024.100025","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 by The American Society of Hematology.","name":"copyright","label":"Copyright"}],"article-number":"100025"}}